We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

139 hedge funds and large institutions have $1.06B invested in Arcutis Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 68 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,579% more call options, than puts

Call options by funds: $5.86M | Put options by funds: $349K

258% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 19

218% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 11

21% more funds holding

Funds holding: 115 → 139 (+24)

15% more capital invested

Capital invested by funds: $914M → $1.06B (+$142M)

3.17% more ownership

Funds ownership: 95.44% → 98.61% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
139
Holders Change
+24
Holders Change %
+20.87%
% of All Funds
2.39%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
35
Increased
68
Reduced
19
Closed
11
Calls
$5.86M
Puts
$349K
Net Calls
+$5.51M
Net Calls Change
+$1.91M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$40.7M
2
State Street
State Street
Massachusetts
+$28.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$27.6M
4
CAM
Cormorant Asset Management
Massachusetts
+$22.7M
5
Jennison Associates
Jennison Associates
New York
+$21.6M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$44.9M
2
OFM
Omega Fund Management
Massachusetts
-$13.3M
3
EC
EcoR1 Capital
California
-$10.9M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.2M
5
Invesco
Invesco
Georgia
-$4.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
51
Millennium Management
New York
$1.64M +$1.95M +85,897 New
Norges Bank
52
Norges Bank
Norway
$1.55M +$451K +19,896 +33%
Citadel Advisors
53
Citadel Advisors
Florida
$1.54M -$2.54M -111,996 -58%
D.E. Shaw & Co
54
D.E. Shaw & Co
New York
$1.42M +$1.69M +74,376 New
Two Sigma Advisers
55
Two Sigma Advisers
New York
$1.36M +$1.61M +71,200 New
Prudential Financial
56
Prudential Financial
New Jersey
$1.28M +$7.7K +340 +0.5%
Renaissance Technologies
57
Renaissance Technologies
New York
$1.24M +$1.23M +54,200 +502%
Two Sigma Investments
58
Two Sigma Investments
New York
$1.2M +$1.42M +62,808 New
Susquehanna International Group
59
Susquehanna International Group
Pennsylvania
$1.16M +$585K +25,814 +74%
California State Teachers Retirement System (CalSTRS)
60
California State Teachers Retirement System (CalSTRS)
California
$987K +$248K +10,932 +27%
CC
61
Centiva Capital
New York
$956K +$1.13M +50,000 New
ECM
62
ExodusPoint Capital Management
New York
$899K +$1.07M +47,055 New
JAFL
63
Jay A. Fishman Ltd
Michigan
$894K +$585K +25,800 +123%
RhumbLine Advisers
64
RhumbLine Advisers
Massachusetts
$854K +$75.4K +3,329 +8%
JP Morgan Chase
65
JP Morgan Chase
New York
$833K +$236K +10,434 +32%
State of Wisconsin Investment Board
66
State of Wisconsin Investment Board
Wisconsin
$804K +$315K +13,889 +49%
Swedbank
67
Swedbank
Sweden
$699K +$829K +36,600 New
VOYA Investment Management
68
VOYA Investment Management
Georgia
$676K +$504K +22,246 +169%
CS
69
Credit Suisse
Switzerland
$665K +$388K +17,112 +96%
Thrivent Financial for Lutherans
70
Thrivent Financial for Lutherans
Minnesota
$649K +$768K +33,914 New
AA
71
ALPS Advisors
Colorado
$627K +$52.4K +2,314 +8%
DekaBank Deutsche Girozentrale
72
DekaBank Deutsche Girozentrale
Germany
$565K +$363K +16,000 +114%
AllianceBernstein
73
AllianceBernstein
Tennessee
$541K – – –
MAM
74
Martingale Asset Management
Massachusetts
$519K +$614K +27,108 New
FAM
75
Fred Alger Management
New York
$503K +$596K +26,324 New
1 2
3
4 5

ARQT Hedge Fund Activity: Q3 2022 in Review

139 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2022, worth a combined $1.06B — up 15% from $914M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ARQT positions and 11 closed out — a net gain of 24 holders — while 68 added to existing stakes and 19 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $40.7M. The largest seller was OrbiMed, cutting an estimated $44.9M.

  • 139 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $1.06B of Arcutis Biotherapeutics stock for Q3 2022, up 15% quarter-over-quarter.
  • 35 funds opened new Arcutis Biotherapeutics positions in Q3 2022 and 11 closed out, a net change of +24 holders.
  • The largest Arcutis Biotherapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $40.7M added.
  • The largest Arcutis Biotherapeutics seller in Q3 2022 was OrbiMed, an estimated $44.9M sold.

Based on aggregated 13F filings for Q3 2022.